Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Tesevatinib |
Synonyms | |
Therapy Description |
Tesevatinib (XL647) is an inhibitor of multiple receptor tyrosine kinases, including ERBB2 (HER2), EGFR, VEGFR2 and VEGFR3, and EphB4, potentially resulting in decreased tumor growth and angiogenesis (PMID: 17575237, PMID: 30030583). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Tesevatinib | KD019|XL647|EXEL 7647|KD 019 | EGFR Inhibitor (Pan) 62 EPHB4 Inhibitor 6 HER2 Inhibitor 42 VEGFR2 Inhibitor 37 VEGFR3 Inhibitor 6 | Tesevatinib (XL647) is an inhibitor of multiple receptor tyrosine kinases, including ERBB2 (HER2), EGFR, VEGFR2 and VEGFR3, and EphB4, potentially resulting in decreased tumor growth and angiogenesis (PMID: 17575237, PMID: 30030583). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02844439 | Phase II | Tesevatinib | Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma | Completed | USA | 0 |
NCT02616393 | Phase II | Tesevatinib | Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases | Completed | USA | 0 |